Amicus Therapeutics Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 20,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $8.00, for a total transaction of $164,000.00. Following the transaction, the chief financial officer now owns 56,450 shares in the company, valued at approximately $451,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Amicus Therapeutics Inc. (NASDAQ:FOLD) opened at 7.80 on Wednesday. The firm’s market cap is $1.11 billion. Amicus Therapeutics Inc. has a 52-week low of $4.98 and a 52-week high of $14.48. The firm has a 50-day moving average of $7.08 and a 200 day moving average of $6.95.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.07. On average, equities research analysts forecast that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current year.
A number of research analysts recently commented on FOLD shares. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a research note on Monday, July 25th. Chardan Capital set a $15.00 price objective on shares of Amicus Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 11th. Finally, Leerink Swann reiterated an “outperform” rating and set a $19.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a research note on Tuesday, June 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Amicus Therapeutics has an average rating of “Buy” and an average price target of $12.19.
A number of institutional investors have recently added to or reduced their stakes in FOLD. BlackRock Fund Advisors raised its position in Amicus Therapeutics by 1.6% in the first quarter. BlackRock Fund Advisors now owns 5,444,399 shares of the biopharmaceutical company’s stock worth $46,005,000 after buying an additional 83,654 shares during the period. M&T Bank Corp purchased a new position in Amicus Therapeutics during the first quarter worth approximately $157,000. Pacad Investment Ltd. raised its position in Amicus Therapeutics by 42.9% in the first quarter. Pacad Investment Ltd. now owns 83,990 shares of the biopharmaceutical company’s stock worth $710,000 after buying an additional 25,231 shares during the period. DekaBank Deutsche Girozentrale raised its position in Amicus Therapeutics by 31.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 70,900 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 17,000 shares during the period. Finally, GW&K Investment Management LLC raised its position in Amicus Therapeutics by 86.5% in the first quarter. GW&K Investment Management LLC now owns 417,435 shares of the biopharmaceutical company’s stock worth $3,527,000 after buying an additional 193,560 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.